StockWatch
·

Sigachi Industries Ltd Q2 FY27 Results

SIGACHIQ2 FY27 Results
Filing
Result:Steady· Market: Down#Margin expansion#Base effect

Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue130.467.6%18.1%
Total Income130.686.9%15.7%
Expenditure119.616.6%8.5%
PBT11.079.7%48.9%
Net Profit8.787.8%16.6%
OPM—
NPM6.72%0.06pp2.60pp
EPS0.2750.0%3.6%
View full financials

Revenue grew 18.1% YoY to a 6-quarter high and EBITDA margin expanded sharply to ~14.65% (from a fire-depressed ~6.8% base), with adjusted PAT (ex one-off) up 49.5% YoY, making the headline -16.6% PAT decline purely a base-effect artifact rather than a core deterioration.

SIGACHI · Q2 FY27 · THE VERDICT

Growth masked by margin squeeze

Revenue jumped 18% year-on-year, but profits fell 16.6% — a divergence that explains why management cut FY27 guidance by ₹50 crore. The quarter exposes structural cost pressures the company is still working through.

05 Nov 2026 · 6 min read
Revenue

₹130.5 Cr

+18.1% YoY

PAT

₹8.8 Cr

-16.6% YoY

Net margin

6.7%

vs ~8% prior year

EBITDA margin

14.7%

vs 18% target

On the surface Q2 looks like a solid quarter: revenue hit ₹130.5 crore, a healthy 18% year-on-year climb. But the profit story tells a different tale. Net profit fell 16.6% to ₹8.8 crore despite that top-line growth. That gap — the divergence between what revenue is doing and what profit is doing — is the quarter's defining story.

Where the margin went

Sigachi's Q2 EBITDA came in at ₹19.2 crore, a 14.72% margin. Management had guided for an 18% full-year average. That's a 328 basis point miss in a single quarter. The company is betting on H2 to deliver margins of 18% or higher to make up the shortfall — but the structural headwind is visible: rising input costs or pricing pressure (or both) are squeezing the bottom line even as sales grow. The net profit margin compressed from roughly 8% last year to 6.7% this quarter. Price realization has improved — the company achieved ₹262.83 per unit in Q2 vs ₹241.36 in Q1 — a 21.6% year-on-year jump. But that price strength is not enough to offset cost inflation.

Management's claims vs. what holds up

Q2+ will see quarter-on-quarter revenue and margin improvement

Revenue +7.6% QoQ (Q2 vs Q1), PAT +7.8% QoQ. But YoY PAT fell 16.6% — margin squeeze persists.

Overstated

FY27 revenue target of ₹650–675 Cr is achievable

CFO revised guidance to ~₹600 Cr due to MCC expansion delay from Q1 FY28 to Q2 FY28.

Contradicted

Full-year EBITDA margin will average 18%

Q2 delivered 14.72%. H2 would need 18%+ to achieve the annual target. Execution risk high.

At Risk

MCC 12K MTPA expansion and CCS 1.8K MT facility to commission Q2 FY28

Still on track for Q2 FY28, but delayed 6 months from the Q1 FY28 initial timeline.

Delayed, not off

What changed on this call

Revenue guidance slashed ₹50 crore: The big headline. From ₹650 crore down to ~₹600 crore. That's a 7.7% haircut driven entirely by the 6-month postponement of the MCC capacity expansion from Q1 FY28 to Q2 FY28. H1 FY27 has delivered ₹250 crore, so H2 needs ₹350 crore to hit the ₹600 crore full-year target. That's more plausible than the prior ₹650–675 guidance, but still hinges on execution.

API order book ramp — the upside flag: The company's active pharmaceutical ingredients business achieved a ₹38 crore order book in Q2 and is targeting ₹100+ crore by year-end. Q2 API revenue was ₹16.7 crore (13% of total), but management indicated that some Q2 revenue was deferred to Q3 at customer request. The trajectory is the story here: API is moving from a niche contributor to a material driver of both growth and margins (higher-margin co-processed grades are the focus).

Capacity utilization constrained — but temporary: The Hyderabad plant accident earlier in the year forced a safety audit. MCC is running at ~80% utilization, well below capacity. Management flagged that post-November (after safety clearance), the plant can ramp to full capacity. It's a near-term headwind masking the pricing power story.

How the street is positioned

The stock sits at ₹28.1, well above its 52-week low of ₹16.65 and well below its all-time high of ₹95.9 (down 70.7% from the peak). Against the 50-day average (SMA50) at ₹29.94, the stock trades just below; against the 200-day average (SMA200) at ₹24.33, it trades above. Technicals are neutral (RSI 53). But the ownership story is more telling: Foreign institutional investors have trimmed from 3.33% two quarters ago to just 1.25% now — a consistent drift lower. Domestic institutional investors remain absent (0.00%). Promoters hold steady at 36.69%, suggesting no insider selling alarm. An ETF rebalance (SPDR) dumped 37.3 lakh shares on 18 September at ₹29.83, mechanical rather than informed, but the volume trend is now increasing post-result — a sign of renewed retail/short-cover interest, though not institutional conviction.

The market's read is clear: skepticism. The stock's 70% drawdown from ATH reflects the broader sell-off in specialty pharma and the guidance misses. The recent FII trim suggests the street is rotating out, waiting for proof of the margin recovery story and the API ramp. Post-result, volume is picking up, but price hasn't rebounded sharply — there's interest, but not conviction.

The bull-bear ledger
  • Revenue growth solid at +18.1% YoY; volume and price both contributing

  • Price realization up 21.6% YoY; pricing power evident vs. commodity peers

  • API order book ₹38 Cr; on track for ₹100+ Cr by year-end

  • Long-term capacity (30K MTPA post-FY28) structures multi-year optionality

  • PAT fell 16.6% YoY despite +18% revenue — margin squeeze unresolved

  • EBITDA margin 14.7% vs 18% target; H2 recovery assumption is aggressive

  • FY27 guidance cut ₹50 Cr (7.7%); credibility dented

  • MCC capex delayed 6 months; further delays risk FY28 trajectory

  • Capex funding (₹200 Cr) still TBD; debt/equity split unclear; refinancing risk

  • FII trimming (3.33% → 1.25%); institutional confidence waning

Ranked risks — by how much they should concern a holder

Margin compression is structural, not temporary

High

Q2 PAT fell 16.6% despite revenue +18%. Input cost inflation or pricing weakness (or both) is real. If H2 doesn't recover to 18%+ margin, FY27 guidance will miss again and confidence will collapse.

MCC capex delays further

High

Already 6 months late (Q1 FY28 → Q2 FY28). Another slip pushes the 30K MTPA capacity target and FY28 earnings tailwind further out. Market is priced for execution; slippage triggers re-rating.

API order book doesn't materialize

High

₹38 Cr order book is visible, but realization risk is real. If Q3-Q4 API revenue disappoints, the growth story for FY28+ loses credibility and the stock re-rates lower.

Capex funding & debt burden

Medium

₹200 Cr capex needs funding; debt/equity split TBD. If debt is raised at higher rates or equity dilutes significantly, per-share accretion is at risk. Refinancing in a rising-rate environment is a headwind.

Hyderabad accident follow-up reputational or operational hit

Medium

Safety constraints are currently limiting utilization to 80%. If there's a follow-up incident or audit failure, demand could weaken and margins compress further.

Stock valuation doesn't leave room for disappointment

Medium

Despite the 70% drawdown from ATH, the stock is not cheap at forward multiples. If the company misses H2 margin guidance or API ramp-up slows, there's limited upside and meaningful downside. The market has already priced out the bull case; execution is not optionality.

What to watch next
  • 1 · Q3 API revenue — the margin recovery catalyst

    Q2 saw some API customers defer to Q3. That deferred revenue could push Q3 API above ₹16.7 Cr and demonstrate the ramp trajectory. If it does, margins should expand (higher-margin co-processed grades). That's the rebuttal to the bear case. Watch the call narrative closely.

  • 2 · H2 EBITDA margin trends — can the company defend 18%?

    Full-year 18% EBITDA margin requires H2 to be 18%+ to offset Q2's 14.7%. That means either: (a) input costs stabilize/decline, or (b) volume/mix improve enough to offset cost pressure, or (c) pricing power holds. Any of these is possible; all are execution. If H2 Q3 comes in below 17%, the 18% target will miss and credibility will be forfeited.

  • 3 · MCC expansion construction milestone — track civil & equipment status

    Management says 'one year timeline' to Q2 FY28. Watch for investor updates and Q3 call commentary on civil structure completion, equipment procurement, and commissioning readiness. A second 6-month slip would be a major de-rating event.

  • 4 · Capex funding announcement — debt vs. equity split

    The company still hasn't announced how it will fund the ₹200 Cr capex. Insurance receivable (~₹49 Cr net) is expected by Nov-Dec, which eases immediate pressure. But the debt/equity mix matters. High debt adds refinancing risk; high equity dilutes the per-share story.

Sigachi Q2 is a transition quarter masquerading as a growth quarter. Revenue is accelerating and price realization is improving — both are real and material. But the profit collapse tells the honest story: the company is caught between a low-margin, commodity-driven past and a higher-margin, specialty-driven future. That transition is where the value is, but the near-term execution is messier than the guidance (or the market) wants to believe.

The guidance cut from ₹650 Cr to ₹600 Cr is the call's most important moment. It flags that the company is recalibrating expectations — and that the MCC expansion delay is not a cosmetic slip but a material cash-flow and earnings headwind. The margin miss (14.7% vs 18%) is the second. Together, they say: execution is harder than management signaled, near-term is at risk, but long-term optionality (30K MTPA MCC, API scaling) is still there.

For a holder, the key number to watch is not revenue or even profit — it's the H2 EBITDA margin. If it lands at 18% or above, management credibility recovers and the stock re-rates. If it misses again, Sigachi will need to deliver API scale-up or MCC ramp-up proof to restore confidence. At ₹28.1, the stock is pricing in structural risk and a prolonged transition. The upside is there, but it's contingent on execution. The debate is not closed; the next quarter will decide.

Informational and educational content only. Not investment advice.